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Immunomodulatory drugs (IMiDs), including thalidomide deriva-
tives such as lenalidomide and pomalidomide, offer therapeutic
benefit in several hematopoietic malignancies and autoimmune/
inflammatory diseases. However, it is difficult to study the IMiD
mechanism of action in murine disease models because murine
cereblon (CRBN), the substrate receptor for IMiD action, is resistant
to some of IMiDs therapeutic effects. To overcome this difficulty,
we generated humanized cereblon (CRBNI391V) mice thereby pro-
viding an animal model to unravel complex mechanisms of action
in a murine physiological setup. In our current study, we investi-
gated the degradative effect toward IKZF1 and CK-1α, a target
substrate of IMiDs. Unlike WT mice which were resistant to lena-
lidomide and pomalidomide, T lymphocytes from CRBNI391V mice
responded with a higher degree of IKZF1 and CK-1α protein degra-
dation. Furthermore, IMiDs resulted in an increase in IL-2 among
CRBNI391V mice but not in the WT group. We have also tested a
thalidomide derivative, FPFT-2216, which showed an inhibitory effect
toward IKZF1 protein level. As opposed to pomalidomide, FPFT-2216
and lenalidomide degrades CK-1α. Additionally, we assessed the po-
tential therapeutic effects of IMiDs in dextran sodium sulfate (DSS)-
induced colitis. In both WT and humanized mice, lenalidomide
showed a significant therapeutic effect in the DSS model of colitis,
while the effect of pomalidomide was less pronounced. Thus,
while IMiDs’ degradative effect on IKZF1 and CK-1α, and up-
regulation of IL-2, is dependent on CRBN, the therapeutic benefit
of IMiDs in a mouse model of inflammatory bowel disease occurs
through a CRBN–IMiD binding region independent pathway.
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Thalidomide was developed in 1957 by the German pharma-ceutical company Chemie Grünenthal as a sedative and used
by pregnant women to ameliorate morning sickness. Although
thalidomide was found safe among rodents, it was found to cause
severe birth defects when used during the first trimester of preg-
nancy (1, 2). Cereblon (CRBN) was now known as the primary
target of thalidomide’s teratogenicity, although thalidomide-induced
oxidative stress and its antiangiogenic effects have previously
been advanced to explain thalidomide teratogenicity (3–6).
More recently, thalidomide’s degradative effect on CRBN
binding protein, CD147, was evidenced as one of the down-
stream signals for teratogenicity (5). Additionally, thalidomide
was shown to inhibit the expression of fibroblast growth factor-8
in the apical ectodermal ridge although it does not have any
effect among mice and rats even if mouse/rat CRBN is nearly
95% homologous to human CRBN (5–7). The reason for ro-
dent resistance toward some of the thalidomide’s therapeutic
use and its side effects remain unknown.
The immunomodulatory drugs (IMiDs) lenalidomide and
pomalidomide promote highly selective recruitment and ubiq-
uitination of proteins to the cullin4A/B
CRBN E3 ubiquitin ligase,
resulting in the degradation of substrate protein via the 26S
proteasome (8, 9). Lenalidomide enables CRBN to target the
lymphoid transcription factors IKZF1 and IKZF3, as well as the
kinase CK-1α, for proteasomal degradation. IMiDs therapeutic
benefit in multiple myeloma (MM) and myelodysplastic syndrome
(MDS) del(5q) rely on the inhibition of these proteins (8–10).
CRBN was first described due to its mutation and deletions in
patients with hereditary mild mental retardation, but at the time
little was known about CRBN’s physiological function (11). Lee
et al. (12) showed that CRBN binds and regulates adenosine
monophosphate-activated protein kinase. Recently, the acety-
lated form of glutamine synthetase (13), MEIS2 (14), Rabex-5
(15), and uridine (16) were proved to be substrate proteins that
bind to CRBN under physiological condition.
Although thalidomide and its derivatives can bind murine
CRBN (6, 14, 17), mouse T cells cannot be stimulated to release
IL-2 by IMiDs (17). Additionally, mouse multiple myeloma cells
are insensitive to lenalidomide treatment (18).
A single amino acid within the CRBN–IMiD binding region
causes mouse CRBN to be resistant toward degradative effects of
IMiDs among selected cullin4A/BCRBN E3 ubiquitin ligase sub-
strates (10). As a result, IMiD activity in murine systems cannot be
extrapolated to human systems. Krönke et al. (10), shown that
lenalidomide treatment of mouse cell line Ba/F3 and primary
mouse hematopoietic cells do not change CK-1α levels. To better
define the in vivo molecular mechanisms underlying mysterious
actions of IMiDs and to delineate species-specific IMiDs actions, we
developed an animal model; mice carrying a humanizing mutation
[CRBNI391V] at the IMiD binding region.
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study of IMiDs.
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IMiDs have the therapeutic benefit not only in malignancy but
also in diseases characterized by an inflammatory phenotype.
Inflammatory bowel disease (IBD), including Crohn’s disease
(CD) and ulcerative colitis (UC), is a chronic inflammation of
the gastrointestinal tract. It is generally accepted that colonic
inflammation results from dysregulation of the mucosal immune
responses to intestinal flora together with genetic and environ-
mental factors (19, 20). Inflammatory cytokines such as tumor
necrosis factor α (TNF-α), interleukin (IL)-1β, IL-23, and IL-17
have been implicated in the pathogenesis of UC (21, 22). IMiDs
antiinflammatory properties gave us the interest to look for their
ameliorative effect in IBD and explain their mechanism of action
which is unknown. In the present study, we used dextran sodium
sulfate (DSS)-induced acute colitis in mice to assess IMiDs’
therapeutic benefit and their mechanism of action.
Results
Generation of Humanized Cereblon Mice, CRBNI391V. The inability to
investigate IMiD properties in murine systems has significantly
hampered research into understanding the drug mechanism of ac-
tion. To overcome this difficulty, we generated mice with cereblon
carrying a single amino acid change at position 391 (CRBNI391V),
where isoleucine was replaced with the valine amino acid counter-
part of human CRBN (SI Appendix, Figs. S1 and S2) using the
CRISPR/Cas9 system. A 295-bp region surrounding the I391 coding
exon (SI Appendix, Figs. S3 and S4) was amplified and cloned into
pCAG–EGxxFP and injected into an oocyte. Mutations screened in
offspring by restriction digestion with FspI enzyme and reconfirmed
with sequencing (SI Appendix, Figs. S1C and S2). Humanization
of cereblon in mice did not result in any observable phenotypic
difference.
Humanized Cereblon Mice Respond to IMiD Treatment. IMiDs coac-
tivate T cells stimulated with anti-CD3e (23). Although such kind of
T cell activation is noticed in a human primary cell or cell line,
murine T cells are known to be resistant to IMiD T cell modulation.
In this study, T cells derived from humanized CRBN mice
(CRBNI391V) were found to be highly sensitive toward IMiD
treatment. IMiDs resulted in a higher level of IL-2 production in
naïve CD4+ T cells isolated from humanized CRBN mice, whereas
WT mice remained unresponsive toward IMiDs activity in an
in vitro setting (Fig. 1). Under these conditions, drug treatment did
not affect the cell viability (SI Appendix, Fig. S5).
Cereblon Modulator, FPFT-2216, and Immune Modulation Activity.
We have tested the immunomodulatory activity of a thalido-
mide derivative, FPFT-2216 (SI Appendix, Fig. S6). We found
that FPFT-2216 highly up-regulates the production of IL-2 al-
though it is less potent than that of pomalidomide (pomalido-
mide > FPFT-2216 ≥ lenalidomide) (Fig. 2A). Furthermore,
FPFT-2216 degrades IKZF1 as well as CK-1α among ubiquitin–
proteasomal degradative substrates of IMiDs (Fig. 2B). Immuno-
modulation activity of FPFT-2216 was comparable in the human
cell line, Jurkat T cell line, both in terms of IL-2 production (SI
Appendix, Fig. S7A) and the degradation of IKZF1 and CK-1α (SI
Appendix, Fig. S7B).
In Vivo IMiD-Treated Humanized Cereblon Mice Mirror in Vitro Activity.
To assess in vivo activities of IMiDs in mouse physiological setup,
a mouse was administered with lenalidomide (100 mg/kg), poma-
lidomide (50 mg/kg), and FPFT-2216 (30 mg/kg) for 14 h and naïve
CD4+ T cells were isolated from spleen. Western blot analysis
revealed significant degradation of CK-1α, and IKZF1 among
CRBNI391V but WT mice were resistant to IMiD administration.
Pomalidomide treatment did not affect CK-1α level, similar to
human cells (10) (Fig. 3). As shown in Fig. 3, the route of admin-
istration did not affect the efficacy of IMiDs in mice as the degra-
dative effect toward cullin4A/BCRBN E3 ligase substrates were
similar when administered orally (Fig. 3A) or intraperitoneally
(Fig. 3B).
Lenalidomide and Pomalidomide Provide Anti-DSS Colitis Therapeutic
Benefit. Thalidomide inhibits TNF-α production (24). We in-
vestigated IMiD activity toward Toll-like receptor-4 (TLR-4)–
activated cytokine production. Peritoneal macrophages were
treated with lenalidomide (50 μM), pomalidomide (10 μM), or
dimethyl sulfoxide (DMSO) (control), 2 h before stimulation
with lipopolysaccharide (LPS). We found that the suppressive
effects of IMiDs toward TNF-α production in both CRBNI391V
as well as WT mice were comparable (SI Appendix, Fig. S8). To
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Fig. 1. Humanized cereblon mice respond to IMiD activity. (A) Naïve CD4+ T cells stimulated with anti-CD3e (5 μg/mL) and simultaneously treated with DMSO or
lenalidomide (10 μM) for the indicated time points. The IL-2 level was measured by ELISA. (B) IL-2 production was measured by RT-PCR at the indicated time points.
Data are shown as the mean ± SEM of three independent experiments. (n.s, nonsignificant; P > 0.05, P < 0.05, **P < 0.01, ***P < 0.001; Student’s t test).
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assess the anti-IBD activity of IMiDs, acute colitis was induced in
8-wk-old male CRBNI391V and WT BDF1 mice using 3% DSS
(Fig. 4A) to develop typical symptoms of IBD, including body
weight loss, diarrhea, and rectal bleeding. DSS administration
for 6 d resulted in severe diarrhea, blood in stool, and body
weight loss (Fig. 4 D–F).
The protective effects of lenalidomide (50 mg/kg) and poma-
lidomide (50 mg/kg) were evaluated after daily administration to
the mice along with DSS. As shown in Fig. 4D, body weight
dramatically dropped by DSS induction compared with the ve-
hicle group. The body loss caused by DSS treatment was signif-
icantly improved in mice receiving lenalidomide. Pomalidomide
helped in regaining the loss of body weight due to DSS admin-
istration although its effect was not as potent as that seen in
lenalidomide-treated groups (Fig. 4D).
Furthermore, macroscopic examination of the colon revealed
that mice treated with DSS had shorter colons than that in the
control group. Lenalidomide (50 mg/kg) treatment attenuated
colon shortening upon DSS intake (Fig. 4 B and C), indicating
less severe inflammation in the colon.
However, pomalidomide (50 mg/kg) treated groups showed
little recovery in the colon length (Fig. 4 B and C).
DSS treatment resulted in bloody stool with further colonic in-
flammation and damage to the intestinal epithelial cell architecture.
As shown in the histological image (Fig. 4G), severe crypt destruc-
tion and inflammatory cell infiltration were reduced in the histo-
logical sections from lenalidomide-treated groups. This ameliorative
effect was less observed among pomalidomide-treated mice.
To evaluate the inflammatory cell infiltration in the colon,
myeloperoxidase (MPO) activity in mice colonic tissues were
BA
Fig. 2. Cereblon modulator, FPFT-2216, results in up-regulation of IL-2 production and degradation of IKZF1 and CK-1α. (A) Naïve CD4+ T cells treated with
lenalidomide (100 μM), pomalidomide (10 μM), FPFT-2216 (10 μM), and IL-2 production measured by ELISA. P values for WT were nonsignificant for com-
parison between IMiDs and DMSO (P > 0.05). For I391V, P < 0.05 for all comparisons between IMiDs and DMSO. Student’s t test was used to calculate statistical
significance. Data are shown as the mean ± SEM of three independent experiments. (B) Naïve CD4+ T cells were treated as A and Western blot analysis was
done for IKZF1 and CK-1α.
DMSO
Len 100μM
Pom 10μM
FPFT-2216 10μM
+
+
+
+
++
+ +
_
_
__ _
_
_
_
_ _
__
_ ___
_ _ _
_ _
__
_
I391V WT
IB:CK-1α
IB:IKZF1
IB:β-actin
DMSO
Len 100μM
Pom 10μM
FPFT-2216 10μM
+
+
+
+
++
+
_
_
__ _
_
_
_
_ _
__
_ ___
_ _ _
_ _
__
_
I391V WT
IB:CK-1α
IB:IKZF1
IB:β-actin
A B
+
Fig. 3. In vivo administration of immunomodulatory drugs result in degradation of cullin4ACRBN E3 ligase substrates. (A) Mice were administered 200 μL of
control, lenalidomide (100 mg/kg), pomalidomide (50 mg/kg), FPFT-2216 (30 mg/kg) solubilized in 0.5% carboxymethylcellulose/sodium and 0.25% Tween 80
for 14 h orally by gavaging. Murine CD4+ T cells were isolated from spleen and Western blot was done. (B) IMiDs were administered intraperitoneally and
Western blot analysis was done as in A. The data are representative of three independent experiments. n ≥ 3.
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Fig. 4. Lenalidomide protects against DSS-induced colitis. (A) DSS-colitis induction. Mice were given 3% DSS for 6 d and water only for the final 1 d, they
were simultaneously treated with IMiDs and killed on day 7. (B) Colon isolated from DSS colitis-induced mice. (C) Colon length. (D) Clinical score, change in
body weight. P values for WT vs. I391V were nonsignificant for all treatments. P value for DMSO vs. pomalidomide was nonsignificant for WT mice. P value for
DMSO vs. lenalidomide was significant for both WT and I391V. P value for DMSO vs. pomalidomide was significant for I391V. (E) Fecal score (stool consistency)
and (F) hematochezia (level of blood in stool). P values for WT vs. I391V were nonsignificant for all treatments. P values for DMSO vs. all treatments were
significant for both WT and I391V mice (E and F). (G) Histopathological image of colon tissue stained with hematoxylin and eosin. (Scale bar, 10 μm.)
(H) Myeloperoxidase activity from colon tissue was measured using a colorimetric method. All experiments were representatives of two independent
experiments. Data are expressed as the mean ± SEM (n = 6 per group). Student’s t test was used.
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examined. Consistent with histological scores, MPO activity in
the colon of DSS-treated group was higher than the control
group, which was significantly suppressed upon treating mice
with lenalidomide (Fig. 4H). Similar to other DSS colitis clinical
scores, pomalidomide was less effective in its suppressive effect
toward MPO release. Taken together, our results indicate that
lenalidomide can markedly reduce inflammatory cell infiltration
in the colon of DSS-induced colitis mice.
The infiltration of circulating leukocytes into the colon evokes
the release of proinflammatory cytokines such as IL-1β, IL-6,
IFN-γ, and TNF-α (21). To determine whether IMiDs abrogate
the production of proinflammatory cytokines in the colon, thereby
giving a protective advantage to the colonic mucosa, the levels of
IL-6, TNF-α, and IL-1β in the supernatant of cultured colons of
3% DSS exposed mice were measured. As shown in SI Appendix,
Fig. S9, treatment with lenalidomide reduces the levels of TNF-α,
IL-6, and IL-1β although these inhibitions were statistically sig-
nificant only for TNF-α and IL-1β. These data suggest that lena-
lidomide may lessen the damaging effects of DSS by suppressing
the expression of proinflammatory cytokines. These results agree
with Fakhoury et al.’s study (25), where mice were treated with
thalidomide, the lead compound of IMiDs family, resulted in
significant decrease in the amount of proinflammatory cyto-
kine, TNF-α, IL-6, and IL-1β.
Discussion
In our current study, we revealed that a single amino acid sub-
stitution in murine cereblon, CRBNI391V, sensitizes murine CD4+
T cells to IMiDs treatment which are otherwise resistant. While this
manuscript was in preparation others have independently con-
firmed that a single amino acid substitution is sufficient for mice
responsiveness to IMiDs activity (26). Although WT mice were
resistant to most of the thalidomide’s therapeutic and side effect
(5, 10, 17, 18, 27), we found that, upon treating with lenalidomide,
pomalidomide, and FPFT-2216, CD4+ T cells from humanized
cereblon mice resulted in a higher level of degradation of target
IMiD molecule, IKZF1. Concomitantly, CD4+ T cells from hu-
manized cereblon mice produced a higher level of IL-2 upon
treatment with lenalidomide, pomalidomide, and FPFT-2216
in an in vitro setting.
We further asked if IMiDs activity can be reproduced in these
genetically engineered mice. Humanized cereblon mice treated
with IMiDs responded with a higher degree toward CRBN–
IMiD target substrates upon drug administration. IMiDs de-
graded IKZF1 and CK-1α among humanized cereblon mice
reconfirming active E3 ubiquitin ligase degradative activity of
IMiDs in in vivo experiments. Treating mice per oral (by gav-
aging) or intraperitoneally did not affect the degree of activity of
IMiDs among substrates we have tested.
A number of researchers around the globe have tried to find
new CRBN modulatory agents, which may allow a wider range of
application in treating more diseases from malignancy to in-
flammatory diseases. We used a CRBN agent, FPFT-2216, and it
showed a potent ability to degrade IKZF1, a target molecule of
IMiDs in multiple myeloma. In contrast to pomalidomide,
FPFT-2216 triggered the depletion of CK-1α protein level. Since
CK-1α protein is encoded by a gene within the common deleted
region for del(5q) and haploinsufficient expression increases
lenalidomide sensitivity among MDS patients, CK-1α was found
to be a mechanistic basis for the therapeutic effect of lenalidomide
in del(5q) MDS (10). A strong inhibitory effect on the protein
level of CK-1α by FPFT-2216 may make this compound a drug of
choice for MDS treatment if tested.
By way of explanation, Chamberlein et al. (17) have reported
thalidomide and pomalidomide do not induce the formation of
two β-strands in the region of CRBN 346–363. On the other
hand, these two β-strands are formed in the presence of lenali-
domide (17). These β-strand formations were shown to make
structural (geometrical) changes of IMiD binding sites of CRBN
and these structural changes might have a contributing factor
in the differential substrate specificities among IMiD family
drugs. Differential substrate specificities of IMiDs were evi-
denced by the fact that IKZF1 and CK-1α were degraded by
both FPFT-2216 and lenalidomide, whereas pomalidomide was
active toward IKZF1 but its action in degrading CK-1α was very
weak.
As a lead compound of IMiD family drugs, thalidomide was
found to relieve extended complications of Mycobacterium leprae
infection, erythema nodosum leprosum (28). This treatment
benefit of thalidomide was later found to be due to its inhibitory
effect toward TNF-α production (24). Although the mechanis-
tical explanation for TNF-α inhibitory effect of thalidomide re-
mains controversial and unclear (29), other IMiDs, lenalidomide,
and pomalidomide, retain this property.
Previously, our study showed that IMiDs inhibit TLR4-induced
cytokine production through the suppressive effect on the TRIF/
IRF3 pathway (30). These observations were made in murine
peritoneal macrophages, and occurred even in CRBN−/− mice.
This finding shades a light that IMiDs antiinflammatory effect
might not exclusively depend on cereblon-IMiD binding region.
In our current study, we found that IMiDs show inhibitory effect
toward TLR4-activated cytokine production. TNF-α production
was strongly inhibited although its inhibitory effect toward IL-6
was less pronounced.
Humanization of cereblon in mice did not contribute to the
inhibitory effect of IMiD toward proinflammatory cytokines we
have tested. This current finding and previous work by Millrine
et al. (30) strongly suggests that there might be other receptors
apart from cereblon involved in the inhibitory effects of IMiDs
toward TNF-α production. Notably, Handa and coworkers (6)
used a bead coated with the phthalimide side of thalidomide,
exposing the glutarimide moiety during their cereblon discovery
experiment. Using beads attached to the glutarimide moiety of
IMiDs and exposing the phthalimide sidechain might help in
finding different possible contributors to the IMiDs mysterious
activity. Thus, bias in this screening strategy toward glutarimide
binding receptors leaves open the possibility that phthalimide
binding receptors might exist.
Thalidomide was known to be effective for CD treatment (25,
31, 32). Although thalidomide was proven to be an effective
therapeutic drug for CD, its catastrophic side effects have
hampered its use (1, 2). We intended to assess the potential
therapeutic activity of lenalidomide and pomalidomide in DSS
colitis, an experimental model of IBD (33). Mice treated with
3.0% DSS exhibited the predominant clinical symptoms of co-
litis: weight loss, diarrhea, bloody feces, crypt distortion, epi-
thelial injury, reduced colon length, increased mucus secretion
by goblet cells, and inflammatory cell infiltration. Mice treated
with lenalidomide showed an efficient relief from the afore-
mentioned peculiar symptoms of IBD. On the other hand,
pomalidomide-treated mice showed lesser recovery from these
symptoms compared with lenalidomide-treated groups. Lenali-
domide reduced DSS-colitis clinical score, macroscopically visi-
ble damage, and reversed inflammation induced shortening of
colon length. Lenalidomide-supplemented mice showed colon
tissue with healthy histological integrity as well.
In this study, lenalidomide treatment showed a significant rate
of reduction in MPO levels, an indicator of neutrophil in-
filtration, proofing reduction in the infiltration of neutrophils.
These results are in line with previous studies where mice (25) or
rats (31) were treated with thalidomide, the first generation
IMiD from which lenalidomide and pomalidomide derived.
As examined with different parameters, lenalidomide treat-
ment resulted in a higher protective effect toward DSS-induced
inflammatory disease. Lenalidomide’s protective effect was
similar among CRBNI391V and WT mice groups, suggesting that
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CRBN–IMiD binding region did not contribute much to IMiDs
DSS-colitis amelioration effect. Further studies are required to
determine whether CRBN-independent processes are responsible.
The development of this previously unavailable important animal
model provides a proof of concept for the development of drugs
that direct ubiquitin ligases for specific degradation of different
disease-associated proteins. Moreover, it will enable the study of
different disease models that can be cured or relieved with IMiDs
which otherwise will be impossible to test due to lack of a host
animal for drug trial on those specific disease models. As we con-
firmed in this study, IMiDs’ therapeutic activity in DSS colitis seems
independent of amino acid sequences in the CRBN–IMiD binding
region. By contrast, a difference in the single amino acid in the
CRBN–IMiD binding region affects IMiDs E3 ubiquitin ligase
modulation activity for degrading target substrates and up-
regulating IL-2 production (SI Appendix, Fig. S10).
Methods and Materials
Humanized Cereblon Mice Generation. CRBNI391V mice were generated using
CRISPR-Cas9. A 295-bp region surrounding the I391 coding exon was am-
plified and cloned into pCAG-EGxxFP (89684; Addgene) using directional
cloning with Nhe1 and BamHI. The optimal Cas9/guide RNA construct was
isolated according to a previously described method (34) and injected to-
gether with a ssDNA “donor” sequence into BDF1 background oocytes. F0
pups were mated and mutations screened in offspring by sequencing. De-
tails are given in SI Appendix, SI Methods and Materials.
CD4+ T Cell Isolation and Activation. Mouse CD4+ T cells were isolated by immu-
nomagnetic negative selection (Miltenyi Biotec). Cells were plated at 1 × 106 cells
per well in 12-well plates in the presence of anti-CD3e (5 μg/mL) (clone HIT3a) or
(clone 145–2C11). The cells were treated with lenalidomide (100 μM), pomali-
domide (10 μM), FPFT-2216 (10, 20, or 40 μM), or 0.1% DMSO for 14 or 24 h.
In Vivo Mice Experiment. Mice experiments were performed according to
ethical guidelines of Osaka University. Mice were administered by gav-
aging or intraperitoneally with lenalidomide (100 mg/kg), pomalidomide
(50 mg/kg), FPFT-2216 (30 mg/kg), or DMSO for 14 h and CD4+ T cells were
isolated from the spleen. Cells were lysed andWestern blot was done for IKZF1
and CK-1α.
Western Blot, ELISA, and qRT-PCR. Western blot, ELISA, and qRT-PCR were
performed as previously described (15, 30). Details are given in SI Appendix,
SI Method and Materials.
DSS-Colitis Induction, Myeloperoxidase Analysis, and Hematoxylin/Eosin Staining.
Colitis was induced by administering 3%dextran sodium sulfate dissolved in fresh
water (∼40 kDa; Sigma-Aldrich) to 8-wk-old male CRBNI391V and wild-type BDF1
strain mice for 6 d followed by normal drinking water for 1 d. Lenalido-
mide (50 mg/kg), pomalidomide (50 mg/kg), or DMSO were administered
per oral to the DSS-treated animals. Clinical scores were determined based on
previous studies (33, 35, 36). Myeloperoxidase, hematoxylin/eosin staining, and
ELISA were done according to previous studies (33, 35, 36). Details are given in
SI Appendix, SI Method and Materials.
Cell Culture.HEK293T cells were grown in DMEM supplementedwith 10% (V/V)
FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin. Mouse primary T cells,
peritoneal macrophages, and Jurkat T cells were maintained in RPMI supple-
mented with 10% (V/V) FBS, 100 units/mL penicillin, and 100 μg/mL streptomycin
(Nacalai Tesque).
Statistical Analysis. P values were calculated using the Student’s t test. P
values <0.05 were considered statistically significant.
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